AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Wednesday 28 October 2026
News from the 24 hours to Wednesday morning, 28 October 2026.
Tone of the day
+7.5strongly positive
+7.5
Relevant headlines33
Stories12
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by EU clearance for Enhertu to treat HER2-positive breast cancer at an early stage, alongside an approval of Trixeo for adolescents with asthma and positive lung cancer trial results. Support from brokers and talk of a possible move into cancer vaccines reinforced the positive lean, although the postponed PACIFIC-9 readout dampened it a little.
What drove it
- Enhertu EU approval
- positive trial data
- analyst support
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
12 stories · 33 headlines · strongest first
Pharma and healthcare on 28 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| EU authorises Enhertu after surgery in patients with HER2-positive early-stage breast cancer +9.710 headlines today · Several outlets report that the EU has approved Enhertu as an adjuvant therapy for residual disease in early-stage HER2-positive breast cancer, citing a 53% reduction in the risk of recurrence or death. | ||
| +10.0 | EU clearance for post-treatment use in early HER2-positive disease. | |
| +10.0 | European regulator clears Enhertu for early breast cancer, widening its market. | |
| +10.0 | Approval backed by large reduction in recurrence risk. | |
| +10.0 | Approval supported by substantial reduction in recurrence or death risk. | |
| +9.7 | Enhertu secures European go-ahead in early breast cancer. | |
| +9.7 | Enhertu gains European approval. | |
| +9.7 | Regulatory clearance in Europe for early breast cancer use. | |
| +9.5 | Company's own regulatory announcement of EU clearance. | |
| +9.5 | Official notice of adjuvant approval in Europe. | |
| +9.2 | European authorisation granted for key cancer drug. | |
| AstraZeneca CEO says company may develop cancer vaccines +3.95 headlines today · CEO Pascal Soriot says AstraZeneca could move into cancer vaccine development building on mRNA groundwork. | ||
| +4.2 | CEO open to vaccine development; potential new growth area. | |
| +4.2 | Possible expansion into cancer vaccines building on mRNA work. | |
| +3.8 | Potential move into vaccine research per chief executive. | |
| +3.7 | CEO floats entering vaccines; exploratory only. | |
| +3.7 | Considering vaccine development, early and uncommitted. | |
| AstraZeneca shows its oncology pipeline at the 2026 ESMO congress +7.44 headlines today · 14 in all, since 26 October · Coverage looks at AstraZeneca's cancer data presented at ESMO and its sentiment effects. | ||
| +9.2 | Successful late-stage cancer trial results; momentum question raised. | |
| +5.8 | Cancer portfolio portrayed as growth engine versus legacy drugs. | |
| +5.0 | Fresh trial readouts framed as potentially lifting investor mood. | |
| +2.5 | Cancer data presented alongside a quoted share price. | |
| Brokers keep Buy ratings on AstraZeneca +4.94 headlines today · 6 in all, since 27 October · RBC and Jefferies are reported to keep Buy ratings, with Jefferies trimming its dollar target. | ||
| +5.0 | Broker reiterates positive recommendation. | |
| +5.0 | Another broker keeps positive rating. | |
| +3.3 | Analyst ratings with upbeat price forecast range. | |
| +1.7 | Buy rating kept but price target lowered; mildly positive overall. | |
| JP Morgan sees favourable risk-reward for AstraZeneca ahead of 2027 readouts +8.32 headlines today · JP Morgan believes AstraZeneca has an attractive balance of risk and reward, with plenty of news expected in 2027. | ||
| +8.3 | Broker cites strong risk-reward with heavy 2027 data flow. | |
| +8.3 | Broker sees favourable balance of risk and reward on pipeline. | |
| AstraZeneca pushes PACIFIC-9 readout back to the first half of 2027 −4.92 headlines today · 4 in all, since 27 October · Innate Pharma says AstraZeneca has updated the timing of the PACIFIC-9 data readout to 2027. | ||
| −4.2 | Trial data pushed back to 2027, delaying a pipeline readout. | |
| −3.3 | Revised later timing for a trial readout. | |
| Imfinzi regimens cut death risk in lung and bladder cancer +8.31 headline today · 14 in all, since 25 October · A report says that using a drug combination against lung cancer reduces the likelihood of death by 32%. | ||
| +10.0 | Lung cancer combination substantially lowers mortality risk in trial. | |
| EU authorises AstraZeneca's Trixeo for asthma patients aged 12 or older +7.51 headline today · Trixeo has been approved in the EU for asthma in people aged 12 and above. | ||
| +7.5 | EU clearance extends asthma use of Trixeo to adolescents. | |
| AstraZeneca Canada and Breast Cancer Canada back survivorship research +3.31 headline today · The two organisations advance survivorship research together. | ||
| +3.3 | Research partnership supports patient-focused reputation in Canada. | |
| Phase III: AstraZeneca's sone-ve gives gastric cancer patients twice the survival +9.71 headline today · 29 in all, since 26 October · An ESMO commentary asks whether AstraZeneca must narrow expectations for its gastric cancer ADC. | ||
| −1.7 | Question over whether gastric cancer drug expectations must be lowered. | |
| AstraZeneca share price moves +2.71 headline today · 7 in all, since 23 October · The shares are reported down 0.25% while testing resistance. | ||
| −0.8 | Minor share price dip, little substance. | |
| AstraZeneca Q3 results preview for 30 October +2.71 headline today · 5 in all, since 24 October · Pieces note AstraZeneca's results are due on 30 October. | ||
| 0.0 | Simply notes upcoming results date. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.